Innovation | PainSolve
;

Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

Confirm

Innovation &
Pipeline

Finding solutions that improve patients’ lives

We aim to deliver major therapeutic advances by treating patients with a high burden of disease, offering clear benefits for patients and sound health economics for society. Our exciting R&D pipeline includes several new drug candidates and technologies to improve patients’ lives.

At Grünenthal, there is close collaboration between all stakeholders involved in research, and each is equally important. Our networked approach to R&D means that we can interlink and supplement our own expertise with external knowledge, leading to improved outcomes.

Fueling our pipeline with innovation

Latest Updates

The Neurobiology of the Placebo Effect – The 1st PainSolve Webinar

We are delighted to have had Prof. Ulrike Bingel (University Hospital Essen, Germany) host our inaugural PainSolve webinar on the 12th December 2018, titled, ‘Psychological and Neurobiological Mechanisms of Placebo and Nocebo Responses.’

... Discover more

How can the patient experience inform your research?

Chronic pain affects every aspect of patients’ lives. However, the experience of pain is unique to the individual, which is why effective treatment is challenging. This article summarises a patient-centric approach to research that harnesses patient insights to inform the development of new strategies with the potential for greater impact on the lives of those with chronic pain.

... Discover more

Diagnostic Challenges of Small Fibre Neuropathy

In this article Prof. Páll Karlsson (Aarhus University) highlights the need for a gold standard in the diagnosis of small fibre neuropathy (SFN). Prof. Karlsson focuses on the heterogeneity of SFN as a potential cause of this unmet need, by comparing different characteristics of the disease and those of similar diseases.

... Discover more

Diagnostic Challenges of Small Fibre Neuropathy

In this article Prof. Páll Karlsson (Aarhus University) highlights the need for a gold standard in the diagnosis of small fibre neuropathy (SFN). Prof. Karlsson focuses on the heterogeneity of SFN as a potential cause of this unmet need, by comparing different characteristics of the disease and those of similar diseases.

... Discover more
Like
 
Share

Share this with:

These are external links and will open in a new window